Sunday August 20th 2017

Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes

Conclusion: Demographic and clinical characteristics of the TOP MS sample at enrollment are consistent with other community-based MS samples, and the sample appears to be representative of DMT users in the US. TOP MS data can be used to explore the associations between disease-modifying therapy compliance and health outcomes.Trial registration: ClinicalTrials.gov (NCT00819000). (Source: BMC Neurology)

See the article here – 

Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes

Leave a Comment

More from category

Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re
Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re

/About-the-Society/News/Researchers-Co-funded-by-National-MS-Society-Repor [Read More]

U.S. House Democrats Launch Probe Into MS Drug Pricing U.S. House Democrats Launch Probe Into MS Drug Pricing
U.S. House Democrats Launch Probe Into MS Drug Pricing U.S. House Democrats Launch Probe Into MS Drug Pricing

U.S. House Democrats said on Thursday they were launching an investigation into why prices for multiple sclerosis (MS) [Read More]

MassDevice.com +5 | The top 5 medtech stories for August 18, 2017
MassDevice.com +5 | The top 5 medtech stories for August 18, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of [Read More]

Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS
Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS

/About-the-Society/News/Investigators-Recruiting-for-Study-of-ALKS-8700-vs [Read More]

Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS
Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS

/About-the-Society/News/Statement-on-House-Oversight-and-Government-Reform [Read More]